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Abstract: Lepirudin, a recombinant hirudin, is a direct irreversible thrombin inhibitor by 
binding to both free and clot-bound thrombin. It is approved for treatment of heparin-induced 
thrombocytopenia (HIT), which is a serious antibody-mediated drug reaction mostly associ-
ated with the use of unfractionated heparin. Clinical experience during the last 10 years has 
proved the efﬁ  cacy of lepirudin in the management of HIT. The major route of elimination of 
lepirudin is the kidney, accounting for approximately 90% of its systemic clearance. The most 
important adverse reactions are bleeding and the induction of immunologic reactions. The 
risk of bleeding can be reduced by implementing an optimal monitoring and dose adjustment 
strategy, particularly in patients undergoing cardiopulmonary bypass surgery and in those with 
impaired renal function. Development of antihirudin antibodies may enhance the anticoagulant 
effect of lepirudin. Anaphylactic reactions associated with lepirudin therapy are rare. The lack 
of an antidote against lepirudin is still a concern, particularly during cardiopulmonary bypass 
surgery with a heart-lung machine and during artiﬁ  cial renal support. Currently, hemoﬁ  ltration 
using high-ﬂ  ux ﬁ  lter systems is the only available and valid means to manage hirudin overdose. 
Nevertheless, the drug can be safely used if meticulous monitoring strategy is installed.
Keywords: lepirudin, hirudin, heparin-induced thrombocytopenia, direct thrombin inhibitors, 
bleeding
Heparin-induced thrombocytopenia (HIT)
Epidemiology of HIT
Heparin-induced thrombocytopenia (HIT) is a drug-induced antibody-mediated 
immunological reaction resulting in arterial and/or venous thrombus formation. It 
can have serious and life-threatening consequences if it is not identiﬁ  ed immediately 
and managed accordingly.
HIT is signiﬁ  cantly more common in patients treated with unfractionated heparin 
(UFH) than in those treated with low-molecular-weight heparins (LMWH) (Warkentin 
et al 1995; Martel et al 2005) (Table 1).
The frequency of HIT ranges between 0.2% and 3.0%, depending on the study 
population, being more common in surgical than in medical patients (Warkentin et al 
1995; Girolami et al 2003; Prandoni et al 2005; Smythe et al 2007). With an incidence 
rate of 0.3%–0.5%, HIT is relatively uncommon in the critical care setting (Selleng et al 
2007). The frequency of HIT in medical patients on thrombosis prophylaxis with UFH 
and LMWH is also considerably low, 0.51% and 0.084%, respectively (Creekmore 
et al 2006). HIT seems to be more common in acute hemodialysis. In a study on 154 
consecutive patients newly treated with hemodialysis, HIT was suspected in 6 (3.9%) 
and the clinical diagnosis was conﬁ  rmed in all but one patient (Yamamoto et al 1996). 
In contrast, in a UK national survey among patients on long-term hemodialysis, the 
incidence rate of HIT was only 0.32% (Hutchison and Dasgupta 2007). Although HIT 
is clearly less frequent in medical than in surgical patients, it is nevertheless associated Biologics: Targets & Therapy 2008:2(3) 482
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with a similarly high rate of thromboembolic complications 
and high treatment costs (Girolami et al 2003; Creekmore 
et al 2006).
The increasing use of LMWH in thrombosis prophylaxis 
and treatment has contributed to the reduction in the inci-
dence of HIT. However, despite the introduction of newer 
anticoagulants in the clinical routine, UFH still remains the 
anticoagulant of choice in certain medical conditions, par-
ticularly during cardiovascular surgery involving cardiopul-
monary bypass (CPB) and in a sizable proportion of critically 
ill patients, thus maintaining the specter of HIT.
Pathogenesis of HIT
HIT typically occurs 5–10 days after starting on heparin treat-
ment (Warkentin et al 1995). Exposure to heparin molecules 
leads to expression of antibodies of the immunoglobulin G 
(IgG) class that bind to the platelet factor 4-heparin complex. 
This complex interacts with endothelial cells and platelets, 
resulting in activation of the coagulation cascade and forma-
tion of thrombi (Warkentin 2004; Girolami and Girolami 
2006; Greinacher 2006). Thromboembolic complications 
can affect both the arterial and venous system.
Diagnosis of HIT
The diagnosis of HIT is primarily based on the course of 
reduction in platelet count and/or the development of throm-
boembolic event during treatment with heparin (Warkentin 
and Heddle 2003). One must be aware of the possibility 
of this syndrome in any patient receiving either UFH or 
LMWH, including heparin ﬂ  ush for vascular access devices 
and extracorporeal systems.
Meticulous history taking and scrutiny of the course of 
reduction in platelet count are important in the diagnosis of 
HIT. Before considering every thrombocytopenia as HIT, one 
should carefully consider other potential causes of thrombo-
cytopenia depending on the clinical condition of the patient. 
Particularly sepsis, other drug-induced thrombocytopenias 
and pseudothrombocytopenia should be considered. Nev-
ertheless, HIT should always be suspected and appropriate 
management immediately implemented unless it is conclu-
sive that other causes of thrombocytopenia are most likely.
Suspecting HIT in critically ill patients presenting with 
thrombocytopenia while receiving UFH or LMWH may be 
difﬁ  cult. Firstly, the rate of thrombocytopenia in this patient 
group is as high as 30%–50% (Strauss et al 2002; Crowther 
et al 2005). Secondly, critically ill patients often present with 
an overlap of clinical syndromes (eg, disseminated intravas-
cular coagulation, bone marrow suppression, liver failure, 
drug toxicity). This complexity may pose a serious diagnostic 
dilemma regarding HIT. In any case, treatment with heparin 
must be stopped and nonheparin anticoagulation immediately 
started until HIT can be ruled out with certainty.
Laboratory diagnosis of HIT is based on the identiﬁ  ca-
tion of platelet factor 4 antibodies and functional platelet 
agglutination tests. The identiﬁ  cation of HIT antibodies 
alone without any considerable reduction in platelet count 
or thrombocytopenia or thrombosis should not be consid-
ered as HIT (Warkentin and Heddle 2003; Juhl et al 2006; 
Greinacher et al 2007). Most of the asymptomatic patients 
with HIT antibodies do not develop HIT and thus do not 
need any speciﬁ  c treatment. The sensitivity and speciﬁ  city of 
functional tests may be variable, and this may be inﬂ  uenced 
by the laboratory expertise. In general, a negative laboratory 
ﬁ  nding does not necessarily rule out HIT (Warkentin and 
Heddle 2003). A conclusive diagnosis of HIT may thus be 
illusive in a small number of patients.
Management of HIT
The ﬁ  rst step in the management of HIT is to immediately 
stop any solution containing heparin and start with a non-
heparin anticoagulant. Stopping exposure to heparin alone 
is not enough in the management of HIT (Wallis et al 1999). 
Thrombin generation and clot formation as a result of the 
hemostatic activation due to HIT antibodies continue for 
several days or weeks even if heparin is stopped (Greinacher 
et al 1999a; Greinacher et al 1999b; Becker 2000). Therefore, 
nonheparin anticoagulants that do not cross-react with HIT 
antibodies should be administered in order to inhibit thrombin 
or thrombin generation.
Drugs used to treat HIT act by either inhibiting coagula-
tion factor Xa or thrombin. Currently, danaparoid, lepirudin, 
and argatroban are approved for treatment of HIT. Danaparoid 
is a glycosaminoglycuronan isolated from porcine intestinal 
mucosa with an anti-Xa : anti-IIa activity ratio greater than 22. 
Its predominant effect is thus neutralizing factor Xa, thereby 
inhibiting the formation of thrombin. Lepirudin is a recom-
binant hirudin (r-hirudin) that irreversibly binds to both the 
Table 1 Meta-analysis of the risk of heparin-induced thrombocy-
topenia (HIT) during thrombosis prophylaxis with low-molecular-
weight heparin (LMWH) versus unfractionated heparin (UFH) 
(after Martel et al 2005)
 HIT  Thrombocytopenia
LMWH  1/1255 (0.1%)  152/3758 (4.0%)
UFH  31/1223 (2.5%)  238/3529 (6.7%)
Odds ratio  0.1 (0.03–0.33)  0.47 (0.22–1.02)Biologics: Targets & Therapy 2008:2(3) 483
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substrate binding and catalytic sites of thrombin. Bivalirudin, 
another r-hirudin but with a reversible direct thrombin inhi-
bition, is approved by the Food and Drug Administration 
(FDA) for use in patients with, or at risk of, HIT undergoing 
percutaneous coronary intervention. Argatroban is a synthetic 
direct thrombin inhibitor derived from L-arginine, and it 
reversibly binds to the active site of thrombin. This review 
focuses on lepirudin, which is one of the oldest nonheparin 
anticoagulants used in the management of HIT.
Lepirudin
Historical background
Hirudin is a naturally occurring anticoagulant produced by 
the salivary glands of the medicinal leech Hirudo medicinalis. 
For several centuries, the leech had been used for medicinal 
purposes, particularly for bloodletting. Historical data from 
Persia and India show that the leech was used for such pur-
poses as early as about 100 BC.
In his in vitro studies, Haycraft could demonstrate for the 
ﬁ  rst time in 1884 the presence of a substance with anticoagu-
lant properties in the leech extract (Haycraft 1884). The ﬁ  rst 
parenteral anticoagulant treatment with a commercial hirudin 
was reported in 1909 (Engelmann and Stade 1909). However, 
inadequate supplies have made it practically impossible for 
the drug to be used in clinical medicine. The introduction of 
heparin that could be produced in large quantities changed 
the focus of research, and hirudin was almost ignored for 
decades. However, the advent of genetic engineering has 
made large production of the compound possible, one of the 
products of this recombinant approach being lepirudin.
The approval of lepirudin for treatment of patients with 
HIT was based on two prospective studies, the Heparin-
Associated Thrombocytopenia (HAT)-1 and HAT-2 tri-
als, which compared its efﬁ  cacy with a historical cohort 
(Greinacher et al 1999a, b). A recent investigation, the HAT-3 
trial, further underlined the efﬁ  cacy of lepirudin in the man-
agement of HIT (Lubenow et al 2005).
Biochemistry
Hirudin comprises structurally similar single-chain poly-
peptides of 65 or 66 amino acids with a compact amino-
terminal core containing 3 disulphide bonds and an extended 
carboxy terminal with a sulphated tyrosine residue (Dodt 
et al 1984).
Lepirudin ([Leu1, Thr2]-63-desulfatohirudin) has a 
molecular weight of 6979 Da. It is derived from transfected 
yeast cells using recombinant technology. In contrast to the 
natural compound, it is homogenous, comprising 65 amino 
acids, lacks a sulphated tyrosine residue at position 63 (thus 
termed desulfatohirudin), and contains leucine instead of 
isoleucine residue at position 1. Lepirudin has a speciﬁ  c 
activity of approximately 16,000 antithrombin units/mg 
(Bayer Product Monograph 2007).
Pharmacology of lepirudin
Mechanism of action
Lepirudin is a direct and irreversible inhibitor of thrombin, 
which is a key serine protease in the hemostatic system. 
Thrombin is generated via activation of its zymogen, pro-
thrombin, by the prothrombinase complex (factor Xa/factor 
Va). The amount and the velocity of thrombin generation 
are decisive in the development of a stable clot (Hemker 
et al 2006).
Lepirudin forms a stable noncovalent stoichometric 1:1 
complex with thrombin, thereby inhibiting its procoagulant 
effects. It binds both to the substrate binding and catalytic 
sites of thrombin. In contrast to heparin, lepirudin is a direct 
thrombin inhibitor and it inhibits not only free but also clot-
bound thrombin (Weitz et al 1990).
The effect of lepirudin on thrombin is well described 
using the thrombin generation assay. Under physiological 
conditions, a very small amount of thrombin is generated 
in the initiation phase of the coagulation process, which is 
then followed by the ampliﬁ  cation and propagation phases, 
culminating in the formation of a large amount of thrombin 
(Hoffman and Monroe 2001; Roberts et al 2006). Lepi-
rudin prolongs the lag phase during thrombin generation. 
In therapeutic doses of lepirudin, the amount of generated 
thrombin (area under the thrombin generation curve) may 
be normal (Figure 1). However, with increasing doses of 
lepirudin, thrombin generation can also be reduced (Petros 
et al 2006).
By inhibiting the thrombin-thrombomodulin-induced 
protein C activation, hirudins might theoretically have a 
procoagulant effect. However, there is no evidence for this 
assumption.
Absorption and distribution
Lepirudin is rapidly distributed throughout the extracellular 
space after intravenous (iv) administration. Its volume of 
distribution ranges between 12.2 and 32.1 L (Bayer Product 
Monograph 2007), so that the drug is conﬁ  ned to the extracel-
lular compartment (Markwardt et al 1984; Meyer et al 1990; 
Vanholder et al 1997). Lepirudin does not cross the blood-
brain barrier (Markwardt et al 1988) and it is not detected in 
breast milk (Lindhoff-Last et al 2000b).Biologics: Targets & Therapy 2008:2(3) 484
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The pharmacokinetic properties of lepirudin following an 
iv administration are well described by a two-compartment 
model (Markwardt et al 1984; Nowak et al 1988; Bayer 
Product Monograph 2007). The initial plasma half-life of 
the drug is about 10 minutes, after which it is distributed in 
the extracellular space. Its terminal half-life in young healthy 
volunteers is about 1.3 hours. The bioavailability of the drug 
is also almost 100% with subcutaneous (sc) administration, 
with peak plasma drug concentration achieved in 3–4 hours 
(Verstraete et al 1993; Schiele et al 1994).
Maximum activated partial thromboplastin time (aPTT) 
is reached about 10 min after an iv bolus, 3–6 hours after a 
6-hour continuous iv infusion, and 2–3 hours after sc admin-
istration (Greinacher 2004).
The pharmacokinetic profile of lepirudin remains 
unchanged during repeated administrations, thus drug accu-
mulation is unlikely in healthy state (Nowak et al 1988).
Metabolism and elimination of lepirudin
The primary elimination route of lepirudin is renal, accounting 
for approximately 90% of its systemic clearance (Markwardt 
et al 1991). It is partially hydrolyzed into amino acids in 
the kidney. About 35% of lepirudin is excreted in the urine 
unchanged (Meyer et al 1990; Nowak et al 1992). The sys-
temic clearance of lepirudin is proportional to the glomerular 
ﬁ  ltration rate (Bucha et al 1999b). Therefore, the half-life of 
the drug increases with deterioration of renal function (Nowak 
et al 1992, 1997; Vanholder et al 1997). The systemic clear-
ance of lepirudin in women is about 25% lower than in men, 
and it is 20% lower in elderly patients than in younger patients 
(Bayer Product Monograph 2007). These facts should be taken 
into consideration during lepirudin dosage.
Dosing lepirudin
Renal function must be taken into consideration while decid-
ing on the initial and maintenance dose of lepirudin. Firstly, 
renal function declines with age. Secondly, elderly patients 
are the largest group of candidates for cardiovascular and 
orthopedic surgery. Thirdly, renal function may deteriorate 
during critical illness. Fourthly, serum creatinine is depen-
dent on muscle mass, which declines with age. Therefore, 
simply taking serum creatinine for renal function assessment 
rather than creatinine clearance may result in overdosing 
lepirudin.
The dosing recommendations of lepirudin for HIT are 
given in Table 2.
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Figure 1 Effect of lepirudin on thrombin generation. The lag time increases and the 
area under the thrombin generation curve becomes smaller with increasing dose 
of lepirudin. The thrombin generation assay was conducted in vitro after spiking 
platelet-rich plasma from healthy donors with lepirudin. Platelet count was adjusted 
at 200 × 109/mL.
Table 2 Dosing recommendation for lepirudin use (intravenous administration) for heparin-induced thrombocytopenia (HIT)
Clinical condition  Bolus dose (mg/kg  Maintenance dose
 body  weight) 
HIT with thrombosis  0.40  0.15 mg/kg/h
HIT without thrombosis  none  0.10 mg/kg/h
HIT with thrombosis and   0.20  0.10 mg/kg/h
concomitant thrombolysis
thrombosis prophylaxis in   none  0.10 mg/kg/h
patients with history of HIT
intermittent hemodialysis  0.08–0.10 predialysis  none
Continuous veno-venous  none  0.005 mg/kg/h
hemoﬁ  ltration
cardiac bypass surgery  0.25 and 0.20 in the priming  adjusted based
  ﬂ  uid of the heart-lung machine  on ECT
Except in cardiac surgery, treatment is generally monitored using aPTT, with a target aPTT ratio of 1.5–2.5. In cardiac surgery, anticoagulant monitoring is carried out using 
ecarin clotting time (ECT), which should be 2.5 μg/mL before and 3.5–4.5 μg/mL during the cardiopulmonary bypass.
Dose regimens are taken from the Heparin-Associated Thrombocytopenia (HAT) trials (Greinacher et al 1999a, b; Lubenow et al 2005).Biologics: Targets & Therapy 2008:2(3) 485
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Laboratory monitoring of the anticoagulant effect of 
lepirudin must be conducted 3–4 hours after starting treat-
ment and 3–4 hours after every dose change. Monitoring 
twice daily seems prudent. If the therapeutic range is not 
achieved, the dose should be increased by 20%. In case of 
overdose, lepirudin infusion must be stopped for 2 hours and 
then restarted at 50% of the last dose. Frequent laboratory 
monitoring and corresponding dose adjustments are neces-
sary in patients undergoing CPB procedures.
Monitoring the anticoagulant effect 
of lepirudin
Several assays have been evaluated for monitoring treatment 
with lepirudin, including the global test activated partial 
thromboplastin time (aPTT), ecarin clotting time (ECT) and 
enzyme-linked immunosorbent (ELISA) techniques (Nowak 
2001; Hafner et al 2002).
Due to its inhibitory effect on thrombin, lepirudin results 
in prolongation of both aPTT and prothrombin time (PT). The 
aPTT is generally the current method of choice for monitoring 
treatment with lepirudin in most situations. However, there 
are considerable inter-individual variations in aPTT among 
patients treated with lepirudin. Furthermore, there is no linear 
correlation between aPTT and lepirudin at plasma concentra-
tions of lepirudin greater than 0.6 mg/L (Pötzsch et al 1997b; 
Moser et al 2001; Hafner et al 2002). This may result in 
overlooking toxic doses and the danger of bleeding.
The ECT deﬁ  nes the prolongation of clotting time 
caused by thrombin inhibition alone (Nowak and Bucha 
1996; Pötzsch et al 1997a, b; Koster et al 2000b). Ecarin is 
a metalloprotease obtained from the snake venom of Echis 
carinatus. It cleaves prothrombin, thereby exclusively 
generating meizothrombin, which is biologically similar 
to thrombin. However, meizothrombin cleaves ﬁ  brinogen 
much more slowly than thrombin. Thus, when all of the 
lepirudin in a blood sample is bound to meizothrombin, 
thrombin is no longer inhibited, which in turn results in 
clot formation. ECT shows a linear correlation to wide 
ranges of plasma lepirudin concentrations. Moreover, 
the inter-individual variation is low and the assay is not 
affected by heparin or antiﬁ  brinolytics (Pötzsch et al 
1997b; Nowak 2001; Hafner et al 2002). ECT is more 
suitable than aPTT to monitor the anticoagulant effect of 
lepirudin particularly when higher doses are used, such 
as in CPB surgery.
Despite the merits of ECT measurement, there is no con-
trolled study that proved the superiority of ECT over aPTT 
in reducing bleeding risk.
Antagonizing the effects of lepirudin
There is no speciﬁ  c antidote against lepirudin or any of the 
other hirudin derivatives. This is a major issue in areas where 
high anticoagulant activity may be required, particularly in 
cardiovascular surgery with extracorporeal circulation. In an 
in vitro model, desmopressin was shown to at least partially 
antagonize the effect of hirudin (Ibbotson et al 1991). Other 
animal studies have also reported the use of desmopressin in 
reversing the effect of hirudin (Butler et al 1993; Bove et al 
1996). However, human studies are still lacking. There are 
case reports on the successful use of recombinant activated 
factor VII in lepirudin-induced bleeding (Hein et al 2005; 
Oh et al 2006).
Another means of coping with bleeding due to lepirudin 
can be extracorporeal elimination systems. Some low-ﬂ  ux 
and all high-flux dialysis membranes are permeable to 
r-hirudin and may thus help to lower toxic doses of the drug 
(Bucha et al 1999a). Other authors concluded that modiﬁ  ed 
ultraﬁ  ltration may enhance the elimination of r-hirudin, but 
plasmapheresis seems to provide the most rapid and complete 
elimination of the drug (Koster et al 2000c). However, such 
extracorporeal techniques are not always a practical option 
in emergency situations.
Clinical efﬁ  cacy of lepirudin in patients 
with HIT
The efﬁ  cacy of lepirudin in the management of patients 
with HIT has been proven in the prospective HAT trials 
(Greinacher et al 1999a, b; Lubenow et al 2005). Clinical 
results of HIT treatment are shown in Table 3. The results of 
these studies underscore that once HIT is suspected, treat-
ment should never be delayed. Delay between diagnosis of 
HIT and start of treatment with an alternative anticoagulant 
accounted for 61% of the thromboembolic complications 
observed during the HAT-3 trial. Summarizing the data of all 
patients included in the HAT trials, lepirudin decreased the 
Table 3 Clinical results of treatment of heparin-induced throm-
bocytopenia (HIT) with lepirudin (after Lubenow et al 2005)
Clinical 
condition
Before 
treatment
During 
treatment
After 
treatment
death 0 4.4% 10.2%
limb amputation 1.0% 4.9% 0
new thromboembolic 
event
8.3% 4.4% 1.0%
combination of events 8.8% 11.2% 9.8%
major bleeding 0 19.5% 0Biologics: Targets & Therapy 2008:2(3) 486
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risk for thromboembolic complications by 92.9% (Lubenow 
et al 2005).
A postmarketing drug monitoring program (DMP) 
involving 1329 patients treated with lepirudin has also shown 
the safety and efﬁ  cacy of the drug in routine clinical practice 
(Greinacher 2004). The overall mortality rate attributed to a 
new thrombosis was only 1.4%. These favorable ﬁ  ndings are 
most probably due to increasing knowledge and experience 
of clinicians. Furthermore, in contrast to the HAT trials, in 
which lepirudin was started after the laboratory conﬁ  rmation 
of HIT, treatment of HIT in the DMP series was started once 
HIT was suspected.
Lepirudin in special circumstances
Due to the lack of adequate antidote, the use of lepirudin in 
disease states requiring extracorporeal systems has been a 
concern in critical care medicine and CPB surgery. However, 
observational studies in the last few years have demonstrated 
that this issue may be solved if appropriate monitoring strat-
egy is implemented.
Lepirudin in artiﬁ  cial renal support
There are no large studies available on the safety and efﬁ  cacy 
of lepirudin in patients on artiﬁ  cial renal support. However, 
case reports and observational studies have shown that the 
drug can be safely used in this patient group (Nowak et al 
1997; Bucha et al 1999b; Fischer et al 1999; Saner et al 2001; 
Gajra et al 2007).
Due to the predominantly renal elimination of lepirudin, 
careful drug dosing and coagulation monitoring are neces-
sary to avoid an overdose in patients with renal dysfunction. 
Elimination half-lives of up to 316 hours have been reported 
in dialysis patients (Nowak et al 1992). Vanholder et al 
(1997) reported hirudin half-life in dialysis patients of more 
than 30 times than that in healthy controls. Minor improve-
ments in renal function can result in a shorter elimination 
half-life of lepirudin. Therefore, frequent dose adjustments 
may be necessary in patients with acute renal failure, whose 
renal function may improve during the course of treatment 
(Fischer et al 1999).
The type of dialysis membrane may also affect the 
pharmacokinetics of lepirudin. While most of the low-ﬂ  ux 
dialysis membranes are not permeable to hirudin, high-ﬂ  ux 
membranes may contribute to the elimination of the drug 
(Bucha et al 1999a; Koster et al 2000c).
Repeated exposures to lepirudin may lead to an increased 
incidence of hirudin antibodies, which may result in marked 
reduction in renal clearance of the drug (see below).
Lepirudin in cardiovascular surgery
Anticoagulation in patients with HIT undergoing CPB 
surgery poses a special problem. There is a marked activation 
of the coagulation system due to exposure of circulating blood 
to artiﬁ  cial surfaces in the CPB pump, making high-dose 
anticoagulation mandatory. UFH remained in this situation 
the anticoagulant of choice, because monitoring is easy and 
rapid and an effective antidote is available.
The issue of adequate monitoring and the lack of an 
antidote are very important while using lepirudin during 
CPB. Target lepirudin concentrations during CPB are 3.5 to 
4.0 μg/mL (Pötzsch et al 1997b). Due to theses high doses 
of lepirudin, aPTT is not sufﬁ  cient for monitoring (Pötzsch 
et al 1997b; Hafner et al 2002). On the other hand, the lack 
of an effective antidote implies that an optimal anticoagulant 
monitoring is crucial to minimize the risk of bleeding. The 
introduction of ECT has allowed monitoring of lepirudin in 
high-dose ranges (Pötzsch et al 1997a, b). During CPB sur-
gery, lepirudin dose can be adjusted based on ECT results that 
can be rapidly obtained using whole blood supplemented with 
normal human plasma (Pötzsch et al 1997b). This supple-
mentation is important because CPB-associated hemodilution 
results in hypoprothrombinemia. Reliable ECT data cannot 
be obtained if plasma prothrombin levels are below 70% of 
normal (Koster et al 2000b; Lindhoff-Last et al 2000a).
Observational studies on patients with HIT have shown 
that cardiovascular surgery can be safely performed with 
lepirudin if stringent coagulation monitoring is instituted 
(Pötzsch et al 1997b; Johnston et al 1999; Koster et al 
2000a; Fabrizio 2001; Liu et al 2002). In one prospective 
controlled study comparing lepirudin with heparin in rou-
tine CPB surgery, lepirudin was shown to provide effective 
anticoagulation, but induced a higher postoperative blood 
loss than heparin (Riess et al 2007).
Lepirudin in pregnancy
The use of lepirudin in pregnancy is generally not recom-
mended, because the drug crosses the placenta. In a rabbit 
model, fetal hirudin plasma concentration was 1/60 that of 
maternal concentration (Markwardt et al 1988). Reports on 
the use of lepirudin in pregnancy are rare (Huhle et al 2000; 
Lindhoff-Last and Bauersachs 2002). In general, danaparoid 
is favored, because it does not cross the placenta (Lindhoff-
Last and Bauersachs 2002; Greinacher 2004).
Lepirudin in children
The incidence of HIT in the pediatric population is low (Klenner 
et al 2003; Newall et al 2003; Boning et al 2005), hence Biologics: Targets & Therapy 2008:2(3) 487
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experience with lepirudin in children is anecdotal (Deitcher et al 
2002; Severin et al 2002; Nguyen et al 2003; Knoderer et al 
2006). Lepirudin at an infusion rate of 0.1 mg/kg bodyweight/
hour seems adequate if renal function is normal (Severin et al 
2002; Klenner and Greinacher 2004). Further dose adjustments 
should be made based on coagulation results.
Lepirudin versus other drugs approved 
for treatment of HIT
Direct comparative investigations between the drugs used 
in the treatment of HIT are not existent. Therefore, state-
ments on this issue must be interpreted with caution. 
Retrospective comparison on the efﬁ  cacy of lepirudin and 
argatroban has shown better results with lepirudin than with 
argatroban (Greinacher 2004). However, due to differences 
in study design, it is difﬁ  cult to make a conclusive statement 
(Warkentin 2003). In another retrospective study by Smythe 
et al (2005), effective anticoagulation was achieved in 77.8% 
of argatroban patients and 69.5% of lepirudin patients. Major 
bleeding was documented in 10.3% and 11.5% of patients 
with argatroban and lepirudin, respectively.
In a retrospective study comparing lepirudin with danapa-
roid, there was no signiﬁ  cant difference in efﬁ  cacy between 
the two drugs in HIT patients with thrombosis at baseline 
treated with therapeutic doses (Farner et al 2001).
Complications of lepirudin treatment
Bleeding
Bleeding is the most important and clinically relevant com-
plication of treatment with lepirudin, with an incidence rate 
of 4%–19% (Lubenow et al 2005). The reasons for this wide 
range in the reported bleeding frequencies may be differences 
in the study population and in monitoring of treatment. In 
a post-marketing DMP, the incidence of major bleeding 
episodes in patients with HIT and thrombosis treated with 
lepirudin was 5.4%, which is signiﬁ  cantly lower than that in 
the HAT trials (Greinacher 2004). This may be attributed to 
a greater awareness and experience of physicians in dosing 
and monitoring lepirudin.
Elderly patients, patients with renal dysfunction and 
those with multiple organ dysfunction syndrome may be at 
high risk of bleeding complication. The hemostatic system 
is disturbed in critically ill patients. Besides renal dysfunc-
tion, deterioration in liver function may result in deﬁ  ciency 
in coagulation factors, which can contribute to an increasing 
bleeding risk during treatment with lepirudin.
A further cause of increased bleeding risk during lepi-
rudin administration is the concomitant use of anti-platelet 
drugs such as acetylsalicylic acid or GPIIb/IIIa inhibitors or 
ﬁ  brinolytic drugs.
Another issue is that the dosing generally recommended 
for treatment might be too high for a number of patients, 
who are mainly critically ill patients with at least one organ 
dysfunction (Lubenow et al 2005).
Antibody development
Antibody development against hirudins is common, and this 
can be induced by both iv therapeutic and sc prophylactic 
doses (Greinacher et al 2003a). In one study, the incidence 
of antibodies against r-hirudin was 84% in iv treated patients 
and 50% in sc treated patients (Huhle et al 1999). In another 
study on 196 patients with HIT treated with lepirudin 
(Eichler et al 2000), 44% developed antihirudin antibodies 
of the IgG class, and development of these antibodies cor-
related with the duration of treatment. Antihirudin antibod-
ies are frequent in patients treated with lepirudin for more 
than 5 days.
By binding to lepirudin, antihirudin antibodies alter the 
pharmacokinetics of the drug, resulting in its longer half-
life. Because the drug is mainly eliminated via the kidney, 
formation of lepirudin-antibody complexes may, due to their 
size, impair renal elimination, which may lead to accumula-
tion of the drug. This phenomenon may thus enhance the 
anticoagulant effect of lepirudin (Eichler et al 2000). The 
volume of distribution of these complexes is also decreased, 
indicating that antibody-bound lepirudin is mainly distributed 
in the intravascular compartment (Liebe et al 2002). Elimina-
tion of the drug using dialysis membranes is also hampered 
(Fischer et al 2003). Therefore, close coagulation monitor-
ing is important during lepirudin treatment in patients with 
antihirudin antibodies.
Allergic reaction
Eczema, rash, hot ﬂ  ushes, fever, chills, urticaria, broncho-
spasm, angioedema, and injection-site reactions have been 
reported in conjunction with the administration of lepirudin. 
Severe anaphylactic reactions have ensued in rare cases in 
close temporal relationship with the administration of lepi-
rudin. These reactions were observed within minutes of iv 
bolus lepirudin administration. The risk of anaphylaxis was 
estimated at 0.015% for ﬁ  rst exposure and 0.16% for repeat 
exposure to lepirudin (Greinacher et al 2003b). High titer 
antihirudin antibodies of the IgG class but not of the IgE class 
were found in lepirudin-associated anaphylaxis. Avoiding 
iv bolus administration, if possible, may reduce the risk of 
severe anaphylactic reactions.Biologics: Targets & Therapy 2008:2(3) 488
Petros
Conclusion
Lepirudin has been proved to be effective and safe in the 
management of HIT. The drug is predominantly eliminated 
through the kidney. Therefore, renal function is a major deter-
minant during dose adjustments. Important adverse effects 
are bleeding and development of antihirudin antibodies. The 
risk of bleeding can be reduced with increasing knowledge of 
physicians in dose adjustments and by implementing appro-
priate laboratory monitoring. The development of antihirudin 
antibodies may necessitate dose adjustments, particularly if 
patients are to be treated with lepirudin for more than 5 days. 
Anaphylactic reactions are very rare, and these seem to be 
associated with iv bolus administration of the drug.
Monitoring of lepirudin treatment can be achieved by 
means of aPTT in most circumstances. However, the cor-
relation between aPTT and lepirudin is low at higher plasma 
lepirudin concentrations, such as required in CPB surgery. 
In such circumstances, ECT seems to be a better means of 
drug monitoring than aPTT.
The lack of an antidote against lepirudin is still a concern 
in certain clinical situations, particularly during CPB surgery. 
Nevertheless, increasing knowledge of physicians on the 
pharmacology of the drug and proper drug monitoring can 
help to reduce the risk of bleeding.
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